Frequency of recent parvovirus infection in patients examined for acute reactive arthritis. A study with combinatorial parvovirus serodiagnostics.
OBJECTIVE
To determine the causative role of human parvovirus B19 as a preceding infection in patients examined for acute reactive arthritis (ReA).


METHODS
Sixty adult patients with acute arthritis were screened for evidence of triggering infections. In all patients, cultures of stool specimens and of Chlamydia trachomatis in urethra/cervix, and/or bacterial serology were studied. The timing of primary infection of human parvovirus B19 was determined by measurement in serum of VP2-IgM, VP2-IgG, epitope-type specifity of VP2-IgG, and avidity of VP1-IgG.


RESULTS
Median time from onset of joint symptoms to the rheumatological consultation was five weeks (range 1-62). Of the 60 patients, 35 fulfilled the diagnostic criteria for ReA; in the remaining, the diagnosis was unspecified arthritis (UA). Thirty-six patients had antibodies for the B19 virus. Occurrence of these antibodies did not differ significantly between ReA and UA groups (P = 0.61). Of these 36 patients, 34 had a pre-existing immunity to the B19 virus. Of the two other patients, one had rash and self-limiting polyarthritis with serological evidence of B19 primary infection, and the other had arthritis of the lower extremities with serological evidence of a convalescence period after the B19 primary infection. The latter patient also had antibodies to Yersinia, with a clinical picture typical for ReA.


CONCLUSIONS
In patients examined for acute ReA, the frequency of recent B19 virus infection was 3.3% (2 out of 60). The diagnostic utility of the presented methodology, by using a single serum sample, was evident.
Hannu
T
T
Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital (HUCH), Finland. timo.hannu@ttl.fi
Hedman
K
K
Hedman
L
L
Leirisalo-Repo
M
M
D000208:Acute Disease; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D016918:Arthritis, Reactive / Q000097:blood / Q000276:immunology* / Q000821:virology*; D020650:Combinatorial Chemistry Techniques; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000150:complications* / Q000175:diagnosis* / Q000276:immunology; D016732:Parvovirus B19, Human / Q000276:immunology*; D000091402:Prohibitins; D012698:Serologic Tests / Q000379:methods
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; C000717331:PHB2 protein, human; D000091402:Prohibitins